Interferon-β1b for multiple sclerosis

Expert Review of Neurotherapeutics

Volumn 5, Issue 2, 2005, Pages 153-164

  Burks, Jack ^a,b,c  

^a Multiple Sclerosis Alliance   (United States)

^b UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

^c Multiple Sclerosis Assoc of America   (United States)

Author keywords

Interferon 1b; Multiple sclerosis; Neutralizing antibodies

Indexed keywords

AZATHIOPRINE; BETA1A INTERFERON; CYCLOPHOSPHAMIDE; GLATIRAMER; IMMUNOMODULATING AGENT; IMMUNOSUPPRESSIVE AGENT; INTERFERON BETA SERINE; METHOTREXATE; METHYLPREDNISOLONE; MITOXANTRONE; NATALIZUMAB; STEROID; BETA INTERFERON; IMMUNOLOGICAL ADJUVANT; INTERFERON BETA-1B;

ACUTE LEUKEMIA; CARDIOTOXICITY; DEPRESSION; DISEASE COURSE; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; FLU LIKE SYNDROME; FOOD AND DRUG ADMINISTRATION; HUMAN; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; INFERTILITY; LOW DRUG DOSE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; PATIENT COMPLIANCE; RECURRENT DISEASE; REMISSION; REVIEW; SKIN MANIFESTATION; STEROID THERAPY; CLASSIFICATION; EXPERT WITNESS; HISTORY; IMMUNOLOGY;

ADJUVANTS, IMMUNOLOGIC; EXPERT TESTIMONY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; INTERFERON-BETA; MULTIPLE SCLEROSIS; RECURRENCE;

EID: 15944398345     PISSN: 14737175     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737175.5.2.153     Document Type: Review

References (72)

1. Compston A, Coles A. Multiple sclerosis. Lancet 359, 1221-1231 (2002).
2. Weinshenker BG, Bass B, Rice PGA et al. The natural history of multiple sclerosis: a geographically based study. Brain 112, 133-146 (1989).
3. O'Connor P. Key issues in the diagnosis and treatment of multiple sclerosis; an overview. Neurology 59(Suppl. 3), S1-S33 (2002).
4. Runmarker B, Andersen O. Prognostic factors in a multiple sclerosis incidence cohort with twenty-five years of follow-up. Brain 116, 117-134 (1993).
5. Trapp BD, Ransohoff R, Rudick R. Axonal pathology in multiple sclerosis: relationship to neurologic disability. Curr. Opin. Neurol. 12, 295-302 (1999).
6. Bjartmar C, Kidd G, Ransohoff RM. A real-time insight into disease progression and the role of axonal injury in multiple sclerosis. Arch. Neurol. 58(1), 37-39 (2001).
7. Kuhlmann T, Lingfeld G, Bitsch A, Schuchardt J, Bruck W. Acute axonal damage in multiple sclerosis is most extensive in early disease stages and decreases over time. Brain 125, 2202-2212 (2002).
8. Hawkins SA, McDonnell GV. Bening multiple sclerosis? Clinical course, long term fellow up, and assessment of prognostic factors. J. Neurol. Neurosurg. Psychiatry 67, 148-152 (1999).
9. van den Noort S, Eidelman B, Rammohan K et al. National Multiple Sclerosis Society (NMSS): disease management consensus statement. National MS Society, NY, USA (1998).
10. Goodin DS, Frohman EM, Garmany GP Jr et al. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology 58(2), 169-178 (2002). American Academy of Neurology/Multiple Sclerosis (MS) Council independent evidence-based medicine review of immunomodulating therapies in MS.
11. Pittock SJ, Mayr WT, McClelland RL et al. Change in MS-related disability in a population based cohort: a 10-year follow-up. Neurology 62, 51-59 (2004).
12. Pittock SJ, McClelland RL, Mayr WT et al. Clinical implications of benign multiple sclerosis: a 20-year population-based follow-up study. Ann. Neurol. 56(2), 303-306 (2004).
13. Arnold DL, Matthews PM. MRI in the diagnosis and management of multiple sclerosis. Neurology 58(Suppl. 4), S23-S31 (2002).
14. Simon Jack H. Magnetic resonance imaging in the diagnosis of multiple sclerosis, elucidation of disease course, and determining prognosis. In: Multiple Sclerosis: Diagnosis, Medical Management and Rehabilitation. Burks JS, Johnson K (Eds). Demos, NY, USA, 99-126 (2004).
15. Jubelt B. Post-polio syndrome. Curr. Treat. Options Neurol. 6(2), 87-93 (2000).
16. Lucchinetti CF, Bruck W. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelization. Ann. Neurol. 47, 707-717 (2000). One of a series of papers by Lucchinetti, Arnason and Bruck delineating four distinct, nonoverlapping immunopathology in MS implying that MS may be four separate disease states based on the pathology.
17. Johnson KP, Brooks BR, Ford CC. Glatiramer acetate (Copaxone): comparison of continuous versus delayed therapy in a six-year organized multiple sclerosis trial. Mult. Scler. 9(6), 585-591 (2003).
18. 1b. Mult. Scler. Clin. Lab. Res. 7, S54 (2001).
19. Paty D. Initial symptoms. In: Multiple Sclerosis: Diagnosis, Medical Management and Rehabilitation. Burks JS, Johnson KP (Eds). Demos, NY, USA, 75-80 (2003).
20. Sadovnick AD, Remick RA, Alien J et al. Depression and multiple sclerosis. Neurology 46, 628-632 (1996).
21. Noseworthy JH, Lucchinetti G, Rodriguez G, Weinshenker BG. Multiple Sclerosis. N. Engl. J. Med. 343(13), 938-952 (2000).
22. Dean G. Epidemiology of multiple sclerosis. Neuroepidemiology 3, 58-73 (1995).
23. Sriram S, Stratton CW, Yao S et al. Chlamydia pneumoniae infection of the central nervous system in multiple sclerosis. Proc. Natl Acad. Sci. USA 92, 7440-7444 (1984).
24. Dean G. Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann. Neurol. 55(4), 458-468 (2004).
25. Sriram S, Stratton CW, Yao S et al. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 46(4), 907-911 (1996).
26. Barnett MH, Prineas JW. Early onset multiple sclerosis: a longitudinal study. Neurology 59(7), 1006-1010 (2002).
27. McDonald W, Compston A, Edan G et al. Recommended diagnostic material for Multiple Sclerosis: Guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann. Neurol. 50, 121-127 (2001).
28. Bowling A. Alternative Medicine and Multiple Sclerosis. Demos, NY, USA (2004).
29. 1b in primary progressive multiple sclerosis. Mult. Scler. 10(Suppl. 1), S62-S64 (2001).
30. Hartung HP, Gonsette R, Konig N et al. Miloxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomized multicenter trial. Lancet 360, 2018-2025 (2002).
31. Neuhaus O, Kieseier BC, Hartung HP. Mitoxantrone (Novantrone®) in multiple sclerosis: new insights. Neurotherapeutics 4(1), 17-26 (2004).
32. Pirko I, Rodriguez M. Pulsed intravenous methyiprednisolone therapy in progressive MS. Arch. Neurol. 61(7), 1148-1149 (2004).
33. PianitchTHS, Hirsch RL, Schindler J, Johnson KP. Treatment of multiple sclerosis with γ IFN exacerbations associated with activation of the immune system. Neurology 37(7), 1097-1102 (1987).
34. 1b demonstrating, for the first time, an efficacious treatment to modify the disease course of relapsing-remitting MS.
35. Chiang J, Gloff CA, Yoshizawa N, Williams GJ. Pharmacokinetics of recombinant human interferon-β in healthy volunteers and its effect on serum neopterin. Pharmaceutical Res. 10(4), 567-572 (1993).
36. Witt PL. Pharmacokinetics of interferon-β and the biological markers it induces. In: Interferon Therapy of Multiple Sclerosis. RederA (Eds). M Dekker, NY, USA, 77-93 (1997).
37. Williams GJ, Witt PL. Comparative study of the pharmacodynamic and pharmacologic effects of Betaseron and Avonex. J. Interferon Cytokine Res. 18(11), 967-975 (1998).
38. 1b serum levels in multiple sclerosis patients following subcutaneous administration. Neurology 46, 1639-1643 (1996).
39. Walther EU, Hohlfeld R. Multiple sclerosis: side effects of IFN-β therapy and their management. Neurology 53, 1622-1627 (1999).
40. Shapiro R. Adherence to Interferon β: BETA Nurse Program. Int. J. MS Care 6, 66 (2004).
41. 1b is effective in relapsing remitting multiple sclerosis. Final outcome of the randomized controlled trial. Neurology 45, 1277-1285 (1995).
42. 1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 43, 662-667 (1993).
43. 1b in relapsing-remitting multiple sclerosis. Mult. Scler. 10, 126-138 (2004).
44. 1a over a 2-year period.
45. Durelli L, Verdun E, Barbero P, Bergui M, Versino E; and INCOMIN Trial Study Group. Vartanian T. An examination of the results of the EVIDENCE, INCOMIN, and phase III studies of IFN-β products in the treatment of multiple sclerosis. Clin. Ther. 25, 105-118 (2003).
46. Barbero P, Verdun E, Bergui M et al. High-dose, frequently administered IFN-β therapy for relapsing-remitting multiple sclerosis must be maintained over the long term: the IFN-β dose-reduction study. J. Neurol. Sci. 222(1-2), 13-19 (2004).
47. 1b in multiple sclerosis: comparing two different doses (the OPTIMS Study). Mult. Scler. 10(Suppl. 2), 603 (2004).
48. 1b in treatment of secondary progressive multiple sclerosis. Lancet 352, 1491-1497 (1998).
49. 1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. Brain 123, 2256-2263 (2000).
50. 1b on quantities derived from MT MRI in secondary progressive MS. Neurology 60, 853-860 (2003).
51. 1b. Neurology 60, 1462-1466 (2003).
52. 1b (EUSPMS) in secondary progressive MS: predictors of treatment response. Mult. Scler. 10(Suppl. 2), 600 (2004).
53. 1b in Secondary Progressive MS: impact on quality of life. Neurology 57, 1870-1875 (2002).
54. 1b in secondary progressive MS: clinical and MRI results of a 3-year randomized controlled trial. Neurology 54, 2352 (2004).
55. 1b in patients with multiple sclerosis. European Neurological Society presentation (2004).
56. Pachner A. Anti-IFN-β antibodies in IFN-β-treated MS patients. Neurology 61(Suppl. 5), S1-S34 (2003).
57. Durclli L, Ricci A. Anti IFN antibody in multiple sclerosis. Molecular basis and there impact on clinical efficacy. Frontiers Biosci. 9, 2192-2201 (2004).
58. Sorensen PS, Ross C, Clemmesen KM et al. Clinical importance of neutralizing antibodies against IFN-β in patients with relapsing-remitting multiple sclerosis. Lancet 362, 1148-1191 (2003).
59. Vartanian TK, Zamvil S, Fox E, Sorensen PS. Neutralizing antibodies to disease-modifying agents in the treatment of multiple sclerosis. Neurology 63(Suppl. 5), S42-S49 (2004).
60. Cutter G. Statistical issues in neutralizing antibodies. Neurology 61(Suppl. 5), S38-S39 (2003).
61. Petkau JA. Statistical approaches to assessing the effects of neutralizing antibodies. Neurology 61(Suppl. 5), S35-S379 (1991).
62. 1b: a randomized trial in multiple sclerosis. J. Neurol. 249, 50-56 (2003).
63. 1b: real-world data. Mult. Scler. 9(Suppl. 1), S40 (2003).
64. 1b in the real world. Int. J. MS Care 6(2), 67 (2004).
65. Hunter S. Comfort (comparative study for two high-dose IFNs in MS). Int. J. MS Care 6(2), 69 (2004).
66. 1a. Int. J. MS Care 6(2), 73 (2002).
67. 1a treatment regimens in MS: the EVIDENCE Trial. Neurology 59, 1496-1506 (2004).
68. Arnason BGW. BEYOND-Betaseron® Efficacy Yielding Outcomes of a New Dose. Neurology 62(7 Suppl. 5), A490 (2004).
69. 1b vs. 250 meg every other day. first phase of the BEYOND program. Mult. Scler. 10(Suppl. 2), P589 (2004).
70. 1a in relapsing MS. Neurology 56(12), 1628-1636 (2001).
71. Rudick RA, Sandrock A. Natalizumab: α4-integrin antagonist selective adhesion molecule inhibitors for MS. Neurotherapeuticsm 4(4), 571-580 (2004).
72. Cree BAG, Khan O, Bourdette D et al. Clinical characteristics of African Americans vs. Caucasian Americans with multiple sclerosis. Neurology 11(63), 2039-2045 (2004).